0001193125-21-214113.txt : 20210812 0001193125-21-214113.hdr.sgml : 20210812 20210713161151 ACCESSION NUMBER: 0001193125-21-214113 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Imago BioSciences, Inc. CENTRAL INDEX KEY: 0001623715 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 454915810 STATE OF INCORPORATION: DE FISCAL YEAR END: 1214 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650 325 5156 MAIL ADDRESS: STREET 1: 329 OYSTER POINT BLVD., 3RD FLOOR CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 CORRESP 1 filename1.htm CORRESP

Imago BioSciences, Inc.

329 Oyster Point Blvd., 3rd Floor

South San Francisco, California 94080

July 13, 2021

VIA EDGAR AND E-MAIL

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-6010

 

Attention:    Chris Edwards
   Angela Connell
   Dillon Hagius
   Li Xiao

 

Re:

Imago BioSciences, Inc. Registration Statement on Form S-1 (Registration No. 333-257419)

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration of the effective date of the Registration Statement on Form S-1 (Registration No. 333-257419) (the “Registration Statement”) of Imago BioSciences, Inc. (the “Company”). We respectfully request that the Registration Statement become effective as of 4:30 p.m., Washington, D.C. time, on July 15, 2021, or as soon as practicable thereafter, or at such later time as the Company or its counsel may request via telephone call to the staff. Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Latham & Watkins LLP, by calling Richard Kline at (650) 470-4987 or Benjamin Potter at (650) 470-4809.

Thank you for your assistance in this matter.

 

Very truly yours,
IMAGO BIOSCIENCES, INC.
By:  

/s/ Matthew Plunkett, Ph.D.

  Matthew Plunkett, Ph.D
  Chief Financial Officer

 

cc:

Hugh Y. Rienhoff, Jr. M.D., Imago BioSciences, Inc.

Richard A. Kline, Latham & Watkins LLP

Benjamin A. Potter, Latham & Watkins LLP

C. Brophy Christensen, Jr., O’Melveny & Myers LLP